Orbit Discovery and Endevica Bio in cachexia therapeutics deal
UK-based Orbit Discovery, which calls itself a ‘leader in the discovery of therapeutic peptide hits’, has announced a collaboration.
Orbit has entered into a multi-target research agreement with Endevica Bio, a privately-held US company creating therapeutics for cachexia caused by cancer and other chronic conditions.
The collaboration aims to accelerate Endevica’s development of advanced G-protein coupled receptor (GPCR)-targeting therapeutics on receptor sets both novel and complimentary to its lead compound, which has been shown to be safe and well-tolerated in Phase I trials. Endevica’s tech platform allows for the modification of peptides to modulate activity of GPCRs behind the blood-brain barrier.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze